Venus Remedies Ltd · VENUSREM
₹205 Cr
₹126 Cr
₹137 Cr
₹143 Cr
₹140 Cr
₹117 Cr
₹156 Cr
₹95 Cr
₹168 Cr
₹143 Cr
₹195 Cr
₹109 Cr
₹170 Cr
₹177 Cr
₹195 Cr
₹137 Cr
₹193 Cr
₹180 Cr
₹259 Cr
₹179 Cr
20-quarter listed-company comparison
Pharmaceuticals - I V Fluids Stocks in India
Pharmaceuticals - I V Fluids: Venus Remedies Ltd owns the largest revenue base AND the fastest current growth.
01 · the index people search for
Nifty Pharmaceuticals - I V Fluids Index — Constituents & Performance
All 1 listed Indian Pharmaceuticals - I V Fluids companies are named here, largest first — the same constituent set people search for as the Nifty Pharmaceuticals - I V Fluids index. Every figure on this page is equal-weighted across those companies, so one large constituent cannot set the reading. Each number carries its own as-of date.
- Venus Remedies Ltd₹2.4K Cr
02 · sector relative strength, before individual stocks
Is Pharmaceuticals - I V Fluids outperforming NIFTY 500?
Pharmaceuticals - I V Fluids has outperformed NIFTY 500 by 269% over the last 52 weeks. Over 13 weeks the gap is a lead of 87.6%. 1 of 1 covered company currently beats NIFTY on Mansfield relative strength, so leadership inside the sector is selective. Venus Remedies Ltd is the strongest against the sector itself at 0%.
+87.6%Sector vs NIFTY 500 · 13 weeks
+269.0%Sector vs NIFTY 500 · 52 weeks
1/1Stocks leading NIFTY 500
0/1Stocks leading sector
Sector metric: — as of latest available · unclassified · direction unavailable.
The central tension: current leadership is concentrated, so durability matters more than rank.
Start with scale. Then earnings trajectory. Then business quality. Only after those three agree should price leadership carry much weight.
Bottom line
Pharmaceuticals - I V Fluids has outperformed NIFTY 500 by 269% over 52 weeks and 87.6% over 13 weeks. 1 of 1 covered companies beat NIFTY on Mansfield relative strength, while 0 of 1 beat the sector itself. Venus Remedies Ltd leads with revenue of ₹811 crore, based on 1 of 1 comparable companies through Jun 2026.
Companies
1
complete canonical membership
Combined market value
₹2.4K Cr
Venus Remedies Ltd
Revenue growing
1/1
positive TTM year-on-year growth
Beating NIFTY 500
1/1
positive Mansfield relative strength
Comparing 1 of 1
03 · research priority, made explicit
Best Pharmaceuticals - I V Fluids Stocks in India (Aug 2026), Ranked by Data
4-Factor Sector Score
An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.
Growth & earnings · 35%Capital efficiency · 25%Valuation · 20%Relative strength · 20%
Venus Remedies Ltd has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 97% evidence confidence.
How this score is built, and what the marks mean
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Top 10 Pharmaceuticals - I V Fluids Stocks in India
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Venus Remedies LtdVENUSREM | 79.1/100Favorable setup97% evidence | LEADER | 34.5/35 Revenue 19.4% · PAT 100% · OPM change 8 pp 100% evidence | 20.1/25 ROCE 21.7% · OPM 19% 100% evidence | 12.0/20 P/E 20.5× · PEG 0.46 85% evidence | 12.5/20 RS sector 0% · RS bench 86.5% · 1Y 271%12 of 12 weeks ahead 100% evidence |
| Exact sum: 34.5 + 20.1 + 12 + 12.5 = 79.1 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
04 · what price has already done
Market action
Venus Remedies Ltd has the strongest one-year price move in Pharmaceuticals - I V Fluids at +271%. It also leads on Mansfield relative strength against NIFTY at +86.5%. 1 of 1 covered company is above zero on that measure. Every line covers 313 weekly closes through 2026-08-14.
Price and relative strength
Every company, the sector's own index and NIFTY 500 all start level on the left edge of the window, so only the distance between the lines counts — the highest line has risen the most since then, and the chart at the top of this page is drawn the same way. It opens on one year; the buttons beside it stretch that to three or five.
How far ahead of or behind NIFTY 500 each company has been running, measured against its own recent average of that comparison, so the flat line at zero IS NIFTY 500: above it the company is beating the market, below it the market is beating the company. It opens on one year.
The same measure taken against Pharmaceuticals - I V Fluids itself instead of the whole market, so the flat line at zero is the sector: above it the company is beating its own peers, which is the sharper test of the two. It opens on one year.
05 · the story behind the numbers
Pharmaceuticals - I V Fluids — the story behind the numbers
This is the written read behind the Pharmaceuticals - I V Fluids figures above — what is actually happening in the sector, in words, with the evidence each claim rests on. It is dated 28 Jul 2026. 3 themes are live here.
The Pharmaceuticals - I V Fluids sector analysis for the week ending 2026-07-19 focuses on VENUSREM. The company reported consolidated revenue of ₹259.40 crore for Q4 FY26, marking a 31.24% increase year-on-year and 43.9% quarter-on-quarter. Consolidated net profit surged 126.19% YoY to ₹47.50 crore.
How old this read is: This read comes from our Pharmaceuticals - I V Fluids sector brief dated 28 Jul 2026, so the words here and the numbers above them cover the same few weeks.
What is live in this sector right now
| Live theme | Severity | Evidence on file |
|---|---|---|
| Export-driven business faces FX volatility from raw material imports and shipping delays that could impact margin consistency.Named for VENUSREM | medium | “Export-driven business faces FX volatility from raw material imports and shipping delays that could impact margin consistency.” |
| Stock under Long Term ASM Stage IV surveillance by BSE as of July 2026, indicating exchange monitoring due to price volatility and trading patterns.Named for VENUSREM | medium | “Stock under Long Term ASM Stage IV surveillance by BSE as of July 2026, indicating exchange monitoring due to price volatility and trading patterns.” |
| Injectable pharmaceuticals business exhibits significant quarterly volatility due to lumpy order fulfillment and customer ordering patterns.Named for VENUSREM | low | “Injectable pharmaceuticals business exhibits significant quarterly volatility due to lumpy order fulfillment and customer ordering patterns.” |
Sources: our Pharmaceuticals - I V Fluids sector brief, 28 Jul 2026 · company earnings-call transcripts.
06 · compare level, then change
Revenue Scale & Growth Durability
Venus Remedies Ltd is the only Pharmaceuticals - I V Fluids company on this page, with Revenue of ₹811 crore. The same company also holds the highest Revenue growth, at 19.4%. That is the only usable Revenue reading on this page, current through Jun 2026. Its Revenue series carries 20 reported observations across the 20-quarter window.
What the numbers say: Venus Remedies Ltd is the scale leader at ₹811 crore, Venus Remedies Ltd's growth is 19.4% from a ₹811 crore base, with 20 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale.
LeaderVenus Remedies Ltd · ₹811 crore
GapNot enough peers
Persistence7/8 recent comparable periods
Coverage1/1 companies · 20 observations
Investor read: Venus Remedies Ltd is the scale benchmark; Venus Remedies Ltd is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns.
This conclusion weakens if: Venus Remedies Ltd's growth falls below Venus Remedies Ltd's for two consecutive comparable reports while operating margin also compresses.
Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.
Revenuelargest
Revenue growthfastest growers
Revenue · company comparison
1/1 level · 1/1 change
On every company-comparison chart on this page: solid lines show level, dotted lines show change when “Both” is selected, and a missing report breaks the line rather than being invented.
All-company data · latest reported quarter
In every all-company table on this page, each figure is the company’s latest single reported quarter. The rankings above them use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | Revenue | Revenue growth | Reported |
|---|---|---|---|
| Venus Remedies Ltd VENUSREM | ₹179 Cr | 31% | Jun 2026 |
Full 20-quarter history · every available company
Revenue · reported quarter history
Revenue growth · reported quarter history
Venus Remedies Ltd · VENUSREM
—
—
—
—
-32%
-7.1%
14%
-34%
20%
22%
25%
15%
1.2%
24%
0.0%
26%
14%
1.7%
33%
31%
07 · compare level, then change
Operating Economics & Margin Trend
Venus Remedies Ltd is the only Pharmaceuticals - I V Fluids company on this page, with OPM of 19%. The same company also holds the highest Margin change, at +8 percentage points. That is the only usable OPM reading on this page, current through Jun 2026. Its OPM series carries 20 reported observations across the 20-quarter window.
What the numbers say: Venus Remedies Ltd leads both opm at 19% and margin change at +8 percentage points.
LeaderVenus Remedies Ltd · 19%
GapNot enough peers
Persistence7/8 recent comparable periods
Coverage1/1 companies · 20 observations
Investor read: Venus Remedies Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current margin change signal.
Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.
OPMhighest
Margin changefastest expanders
Operating margin · company comparison
1/1 level · 1/1 change
All-company data · latest reported quarter
| Company | OPM | Margin change | Reported |
|---|---|---|---|
| Venus Remedies Ltd VENUSREM | 19% | +8.0 pp | Jun 2026 |
Full 20-quarter history · every available company
OPM · reported quarter history
Venus Remedies Ltd · VENUSREM
13%
10%
3.9%
10%
9.3%
7.0%
16%
11%
11%
8.0%
10%
10%
4.5%
10%
15%
11%
16%
21%
24%
19%
Margin change · reported quarter history
Venus Remedies Ltd · VENUSREM
+5.0 pp
−4.8 pp
−0.1 pp
−2.8 pp
−4.2 pp
−3.0 pp
+12.1 pp
+0.9 pp
+1.7 pp
+1.0 pp
−6.0 pp
−1.0 pp
−6.5 pp
+2.0 pp
+5.0 pp
+1.0 pp
+11.5 pp
+11.0 pp
+9.0 pp
+8.0 pp
08 · compare level, then change
Profit Scale & Acceleration
Venus Remedies Ltd is the only Pharmaceuticals - I V Fluids company on this page, with Net profit of ₹117 crore. The same company also holds the highest Profit growth, at the 100% top of the scoring scale. That is the only usable Net profit reading on this page, current through Jun 2026.
What the numbers say: Venus Remedies Ltd leads with ₹117 crore of TTM profit, Venus Remedies Ltd shows ≥100% on the scoring scale (112.7% uncapped) growth from a ₹117 crore profit base. Compare the size of the base and persistence before ranking acceleration above profit scale.
LeaderVenus Remedies Ltd · ₹117 crore
GapNot enough peers
Persistence7/8 recent comparable periods
Coverage1/1 companies · 20 observations
Investor read: Venus Remedies Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.
Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.
Net profitlargest
Profit growthfastest growers
Net profit · company comparison
1/1 level · 1/1 change
All-company data · latest reported quarter
| Company | Net profit | Profit growth | Reported |
|---|---|---|---|
| Venus Remedies Ltd VENUSREM | ₹23 Cr | 130% | Jun 2026 |
Full 20-quarter history · every available company
Net profit · reported quarter history
Venus Remedies Ltd · VENUSREM
₹23 Cr
₹6 Cr
₹0 Cr
₹7 Cr
₹5 Cr
₹3 Cr
₹11 Cr
₹1 Cr
₹10 Cr
₹7 Cr
₹11 Cr
₹1 Cr
₹4 Cr
₹20 Cr
₹21 Cr
₹10 Cr
₹20 Cr
₹26 Cr
₹48 Cr
₹23 Cr
Profit growth · reported quarter history
Venus Remedies Ltd · VENUSREM
—
—
—
—
-78%
-50%
—
-86%
100%
133%
0.0%
0.0%
-60%
186%
91%
900%
400%
30%
129%
130%
09 · compare level, then change
Return On Capital Employed
Venus Remedies Ltd is the only Pharmaceuticals - I V Fluids company on this page, with ROCE of 21.7%. The same company also holds the highest ROCE change, at +9.9 percentage points. That is the only usable ROCE reading on this page, current through Jun 2026. Its ROCE series carries 16 reported observations across the 20-quarter window.
What the numbers say: Venus Remedies Ltd leads ROCE at 21.7%. Venus Remedies Ltd has the strongest latest improvement at +9.9 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.
LeaderVenus Remedies Ltd · 21.7%
GapNot enough peers
Persistence7/8 recent comparable periods
Coverage1/1 companies · 16 observations
Investor read: Venus Remedies Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current roce change signal.
ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.
ROCEhighest
ROCE changefastest improvers
Return on capital · company comparison
1/1 level · 1/1 change
All-company data · latest reported quarter
| Company | ROCE | ROCE change | Reported |
|---|---|---|---|
| Venus Remedies Ltd VENUSREM | 24% | +9.9 pp | Jun 2026 |
Full 20-quarter history · every available company
ROCE · reported quarter history
Venus Remedies Ltd · VENUSREM
4.7%
—
6.0%
—
1.6%
—
5.4%
—
6.0%
9.1%
6.1%
8.6%
4.2%
11%
8.6%
14%
12%
17%
17%
24%
ROCE change · reported quarter history
Venus Remedies Ltd · VENUSREM
—
—
—
—
−3.1 pp
—
−0.6 pp
—
+4.4 pp
—
+0.7 pp
—
−1.8 pp
+1.6 pp
+2.5 pp
+5.2 pp
+7.8 pp
+6.7 pp
+8.2 pp
+9.9 pp
10 · compare level, then change
Valuation Against Growth & Quality
Venus Remedies Ltd is the only Pharmaceuticals - I V Fluids company on this page, with PEG of 0.46×. The same company also holds the lowest P/E, at 20.5×. That is the only usable PEG reading on this page, current through Jun 2026. Its PEG series carries 6 reported observations across the 20-quarter window.
What the numbers say: Venus Remedies Ltd has the lowest comparable PEG at 0.46×. Only 1 of 1 companies have earnings and growth steady enough for the ratio to mean anything, so no broad “cheapest stock” conclusion is defensible unless the current multiple, own-history position and growth durability agree.
LeaderVenus Remedies Ltd · 0.46×
GapNot enough peers
Persistence0/8 recent comparable periods
Coverage1/1 companies · 6 observations
Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.
This conclusion weakens if: The next two comparable reports reverse the current p/e signal.
PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.
PEGlowest PEG
P/Elowest P/E
Valuation · company comparison
1/1 level · 1/1 change
All-company data · latest reported quarter
| Company | PEG | P/E | Reported |
|---|---|---|---|
| Venus Remedies Ltd VENUSREM | 0.5 | 25.3 | Jun 2026 |
Full 20-quarter history · every available company
PEG · reported quarter history
Venus Remedies Ltd · VENUSREM
—
—
—
—
0.4
—
—
—
—
2.1
—
2.3
0.3
1.7
—
0.5
—
—
—
—
P/E · reported quarter history
Venus Remedies Ltd · VENUSREM
14.4
9.2
6.9
6.6
7.6
13.4
13.8
12.8
16.2
21.3
15.0
16.8
15.8
18.6
14.4
16.0
12.6
16.6
15.1
25.3
11 · before the conclusion, check the blind spots
What can make this comparison misleading?
This Pharmaceuticals - I V Fluids comparison names 4 specific ways its own evidence can mislead, all listed below. The one company here reports on comparable dates, so no rank carries a stale marker. A high growth rate can still be a low-base artefact.
Keep these limits visible
- A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason.
- A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment.
- The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed.
- An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
12 · evidence and freshness
How was this comparison built?
This comparison is built from the reported filings of 1 Pharmaceuticals - I V Fluids company, normalized to a common ₹ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Jun 2026 and market data through 2026-08-14.
FundamentalsThrough Jun 2026 · up to 20 quarters per company
Market dataThrough 2026-08-14 · weekly price and relative-strength history
Derived metricsGrowth, changes and PEG are calculated only when their inputs are comparable.
Score confidenceMissing and stale evidence reduces confidence and pulls the 0–100 research-priority score toward neutral.
Source standing1 cross-checked · 0 unverified · 0 withheld, of 1 graded companies.
How a second data feed is admitted, and what happens when it disagrees
A second feed is read only after its reported income is matched against the primary source on at least three overlapping periods. Where the two agree the figures fill silently. Where there is too little shared history to compare, the figures are still drawn — they are the only evidence there is — and marked ⚠ unverified everywhere they appear. Where the two are known to disagree, nothing from the second feed is drawn and the affected company is named under the chart it is missing from.
13 · questions investors ask, short speakable answers
Pharmaceuticals - I V Fluids company comparison FAQs
These 23 answers restate the Pharmaceuticals - I V Fluids comparison above in question form. Every one is computed from the same 1 company and the same reported filings as the rankings and charts, current through Jun 2026. Price and relative-strength answers run through 2026-08-14. Nothing here is estimated, and none of it is a recommendation.
Is the Pharmaceuticals - I V Fluids sector outperforming NIFTY 500?
Pharmaceuticals - I V Fluids has outperformed NIFTY 500 by 269% over 52 weeks and 87.6% over 13 weeks. 1 of 1 covered companies beat NIFTY on Mansfield relative strength, while 0 of 1 beat the sector itself.
Which Pharmaceuticals - I V Fluids company is largest by revenue?
Venus Remedies Ltd leads with revenue of ₹811 crore, based on 1 of 1 comparable companies through Jun 2026.
Which Pharmaceuticals - I V Fluids company is growing fastest?
Venus Remedies Ltd has the fastest current revenue growth at 19.4%, across 1 of 1 comparable companies.
Which Pharmaceuticals - I V Fluids company has the strongest 4-Factor Sector Score?
Venus Remedies Ltd ranks first at 79.1/100 with 97% evidence confidence. The score prioritizes research; it is not a buy recommendation.
Which Pharmaceuticals - I V Fluids company has the lowest comparable PEG?
Venus Remedies Ltd has the lowest comparable PEG at 0.46, among 1 of 1 companies whose earnings and growth are steady enough for the ratio to mean anything.
How much history does this Pharmaceuticals - I V Fluids comparison include?
The page compares up to 20 reported quarters per company for fundamentals, returns and valuation, ending Jun 2026. Missing observations remain blank rather than being estimated.
How is the 4-Factor Sector Score calculated?
The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral.
Is there a Nifty Pharmaceuticals - I V Fluids index?
NSE India maintains Nifty indices for several broad sector categories — Nifty Bank, Nifty IT, Nifty Pharma and others — but not for every sub-sector grouping on this site. Whether or not an official Nifty index covers Pharmaceuticals - I V Fluids, this page builds its own equal-weight basket of 1 listed Pharmaceuticals - I V Fluids companies — one company, one vote, regardless of market value — so no single large company dominates the reading. Figures are as of Jun 2026.
Which are the best Pharmaceuticals - I V Fluids stocks in India?
Ranked by this page's four-factor score, Venus Remedies Ltd places first among 1 listed Pharmaceuticals - I V Fluids companies. That is a ranking of published data — earnings, quality, valuation and market behaviour as of Jun 2026 — and not a recommendation; Sector Alpha is not registered with SEBI as an investment adviser.
How many Pharmaceuticals - I V Fluids stocks are listed in India?
This comparison covers 1 listed Pharmaceuticals - I V Fluids companies in India, each above the size floor the site applies, with 20 quarters of reported figures per company where the filings exist. The full ranked list is on this page, as of Jun 2026.
Which Pharmaceuticals - I V Fluids company is the biggest?
Venus Remedies Ltd is the largest, with trailing-twelve-month revenue of ₹811 crore. That covers 1 of 1 companies with comparable reporting through Jun 2026.
Which Pharmaceuticals - I V Fluids company has the best profit margins?
Venus Remedies Ltd has the highest operating margin at 19%, from 1 of 1 comparable companies. Venus Remedies Ltd shows the biggest recent improvement, at +8 percentage points. A high margin matters most when it is holding or rising, not when it is peaking.
Which Pharmaceuticals - I V Fluids company makes the most profit?
Venus Remedies Ltd earns the most, at ₹117 crore of trailing-twelve-month net profit, from 1 of 1 comparable companies. Venus Remedies Ltd has the fastest profit growth at the ≥100% scoring cap, though growth off a small or recovering profit base overstates how much has actually changed.
Which Pharmaceuticals - I V Fluids company earns the highest return on capital?
Venus Remedies Ltd leads on return on capital employed at 21.7%, across 1 of 1 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year.
Which Pharmaceuticals - I V Fluids stock is the cheapest?
On PEG — where a LOWER number is cheaper — Venus Remedies Ltd screens cheapest at 0.46×. All 1 companies qualify for the ratio comparison. Cheap on a multiple is a reason to investigate, never a reason to buy on its own.
Is the Pharmaceuticals - I V Fluids sector beating the market?
Pharmaceuticals - I V Fluids has outperformed NIFTY 500 by 269% over the last 52 weeks and 87.6% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 1 of 1 covered companies are beating the market on their own. Sector strength does not transfer evenly to every stock in it.
Which Pharmaceuticals - I V Fluids stock has the strongest price momentum?
Venus Remedies Ltd has the strongest relative strength against NIFTY 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all.
Which Pharmaceuticals - I V Fluids company scores highest for research priority?
Venus Remedies Ltd scores 79.1 out of 100 with 97% evidence confidence, from 34.5 points on growth and earnings, 20.1 on capital efficiency, 12 on valuation and 12.5 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research.
How many Pharmaceuticals - I V Fluids companies does this comparison cover, and over what period?
It compares 1 listed companies over up to 20 reported quarters of fundamentals, ending Jun 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data.
What is the total market cap of the Pharmaceuticals - I V Fluids sector?
The 1 Pharmaceuticals - I V Fluids companies on this page carry ₹2,382 crore of combined market value. Venus Remedies Ltd is the largest at ₹2,382 crore, about 100% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-08-20.
How is the Pharmaceuticals - I V Fluids sector performing?
1 of the 1 covered Pharmaceuticals - I V Fluids companies are beating NIFTY 500 on Mansfield relative strength. The sector itself is 269% ahead of NIFTY 500 over 52 weeks on an equal-weight index of its current members. Readings are as of 2026-08-20.
Why are some values on this page blank?
A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad.
Is this investment advice?
No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.